http://www.neuronbio.com/Noticias de Neuron BIOhttp://neuronbio.com/Noticias.aspx?id=567Mon, 02 Nov 2015 00:00:00 GMTIt achieves the highest production level known to date. Neol Bio, a subsidiary of Neuron Bio has submitted a patent application for a new method of fatty alcohols production in the use of genetically improved variants of its microorganism Neoleum®. The new biotechnological production method developed by Neol, which uses residual feedstock not competing with human nutrition, consumes less energy, is more efficient and produces fewer pollutants. This new patent from Neol has been possible thanks to the research initiated in 2013 with the genome sequencing of the microorganism Neoleum® and the internal development of genetic engineering tools in order to modify its metabolism. All this opens open the way to new sustainable production processes of oleochemical products. The achieved production levels at the laboratory are higher than all described to date in patents and publications by research groups and international biotech companies. Fatty alcohols are a key ingredient in the oleochemical sector and are present in detergents, cosmetic and pharmaceutical products. Currently the market of fatty alcohols amounting to yearly 5,500 million $ is dominated by Asian companies that produce these compounds from vegetable oils and using chemical methods. ]]>http://neuronbio.com/Noticias.aspx?id=568Thu, 05 Feb 2015 00:00:00 GMTThey propose solutions for the development of bioindustries to obtain high-value products from waste. Three innovative projects from Neol Biosolutions, a company belonging to Neuron Bio, have been preselected in the first phase of public innovative purchase tenders for the project CLAMBER (Castilla La Mancha Bioeconomy Region). The projects presented by Neol propose innovative solutions focused on the development of new bioindustries in the Spanish region Castilla La Mancha to provide high-value products from various types of waste such as Omega-3 rich oils and other microbial oils from diverse agricultural and industrial waste. This first selection phase includes the elaboration of a technical and economic feasibility study. In case the three projects are finally selected for implementation phase, this would represent for the company a turnover of over one million € in 2015. CLAMBER is an initiative of the regional governs from Castilla La Mancha with the collaboration of ASEBIO, the Spanish Bioindustry Association and co-financed by the European Commission. The main goal of this initiative is to position the region Castilla La Mancha next to the European leaders in the so called bioeconomy or industrial biotechnology, in order to obtain alternative bioproducts to petroleum derivates (plastics, fuels, lubricants, dyes …) from renewable and sustainable sources (new crops and wastes of plant and animal origin). A total of 61 proposals were submitted to the selection process, of which 39 have been preselected; among of them 3 are promoted by Neol. This program of public purchase for innovative technology is organized by R&D contracts that cover 100 % of the costs of the final awarded companies. ]]>http://neuronbio.com/Noticias.aspx?id=564Mon, 29 Dec 2014 00:00:00 GMTThe patented compound may be the key to the prevention and treatment for Alzheimer’s disease and other neurodegenerative diseases Thanks to this patent the Spanish biotech company expects to achieve important commercial agreements in coming years The European Patent Office (EPO) has issued the patent "Neuroprotective, hypocholesterolemic and antiepileptic compound" to Neuron Bio on 24 December in order to protect its new compound NST0037, the most advanced of the Spanish biotech company against the Alzheimer’s disease so far. The compound NST0037 has been developed by Neuron Bio from its projects regarding the search of neuroprotective statins that began in January 2007. The patent application was filed in October 2009 and finally it has been recently granted by the European Patent Office. This is one of the most important achievements of the Spanish biotech company for its research activity in the Alzheimer’s prevention, in which the company is an international reference. The patented compound is a new chemical entity derived from the simvastatin that offers improved effects to prevent neurodegenerative processes related to the Alzheimer’s disease and other neurodegenerative diseases associated with the age and with no cure currently. It might also be useful to treat different pathologies of the central nervous system such as Parkinson's disease and Huntington's disease. Fernando Valdivieso, Chairman of the company has evaluated very positively this new “the recent awarded patent is the key to future of Neuron Bio, because it will allow us to move forward the achievement of commercial agreements with pharmaceutical companies interested in the development of molecules with new action mechanisms for the creation of more effective drugs in the fight against the Alzheimer’s.” This patent is an addition and complements the patent granted by the same office the last 30 October 2014 that protect the use of simvastatin as an antiepileptic. So, it is the second European patent achieved by Neuron Bio in its main activity of R&D. ]]>